A team of researchers and patient advocates have addressed the challenges related to traveling after receiving radiation therapy involving Lu-177 dotatate in a study published by Kendi et al in The Journal of Nuclear Medicine.
Due to the residual radiation activity of Lu-177 dotatate, some patients with neuroendocrine tumors who have undergone treatment with the agent have experienced travel delays at U.S. ports of entry. It is recommended that patients carry a travel card containing treatment information after each therapy cycle and for an additional 3 months after therapy has concluded to avoid travel delays.
Photo credit: Getty
"Disruption in travel, especially if not anticipated, can be extremely distressing for patients who have enough to deal with already. For many such patients, this travel is meant to take the mind off of their disease. Being stopped at borders of entry is, without a doubt, potentially traumatic," said senior study author Thorvardur R. Halfdanarson, MD, Professor of Oncology at the Mayo Clinic Cancer Center in Rochester, Minnesota.
Approved by the U.S. Food and Drug Administration (FDA) in 2018, Lu-177 dotatate has been used for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors by over 150 hospitals and medical centers throughout the United States. The radiation activity from the treatment is not harmful to others, but it can be detected by sensitive radiation detectors at international airports and border crossings by boat, car, or foot and can lead to travel delays. Furthermore, the metastable isotope Lu-177m, which is present after treatment with Lu-177 dotatate, can be mistaken for plutonium at ports of entry, as they have coincidental similarities in their radiation signatures. This can contribute to additional wait times.
To alleviate potential delays while traveling, the study authors recommend that patients be given a travel card containing the patient's personal information, type of radiation received, dose of radiation administered, and date of administration. The card should also include information about the treating institution and contact information with 24-hour access if further information is required. In addition, patients should carry a copy of their most recent clinical notes in a single envelope that is easily accessible when going through U.S. ports of entry and high-security areas.
According to Dr. Halfdanarson, providing education for patients and treating physicians is key. Physicians should advise patients that they may be delayed at various points of travel and that they should allow extra time when traveling, especially when transferring between international and domestic flights. Frequent communication between the FDA, Nuclear Regulatory Commission, Customs and Border Protection (CBP), and researchers should continue in order to keep the staff up to date on the current use of medical isotopes and to help CBP make appropriate radiation-detection equipment choices.
Training and improvements in detection technology can help mitigate the travel delays. A public online survey performed by a study author showed that most patients experiencing this issue are treated with respect at the U.S. ports of entry and high-security areas. However, screening procedures took around 1 to 2 hours—and in some cases, even longer. Some patients reported that they had to go through screening with the radiation detectors multiple times, and some of the portable detector systems were not able to correctly identify Lu-177 dotatate, reporting other radionuclides instead.
“All of the new and exciting developments in nuclear medicine therapies are changing how we practice nuclear medicine and molecular imaging. As more therapies using different radionuclides are brought into clinical practice, this change will become more significant,” noted first study author Ayşe Tuba Kendi, MD, Associate Professor in the Division of Nuclear Medicine, Department of Radiology, at the Mayo Clinic. “This unique article is a great example of teamwork, connection, and communication with patients, colleagues and, experts, which are key elements for success of nuclear therapies.”
Disclosure: For full disclosures of the study authors, visit jnm.snmjournals.org.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.